Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag

This article was originally published in PharmAsia News

Executive Summary

J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.

You may also be interested in...

Back To Square One: India's J.B.Chemicals, Dr. Reddy's Terminate Russa Rx Deal

MUMBAI - Less than three months after agreeing to sell its Russia-CIS prescriptions business, Indian drug maker J.B. Chemicals & Pharmaceuticals Ltd. has called-off its deal with fellow Indian drug maker Dr. Reddy's Laboratories Ltd.

J&J Expands Russian OTC Foothold Via J.B. Chemicals Portfolio Acquisition

Johnson & Johnson expands its consumer health presence in Russia and other Eastern European markets with the acquisition of several OTC brands from J.B. Chemicals & Pharmaceuticals

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts